Thus, our results demonstrate the utility of measuring MYC expression as a pharmacodynamic marker of BET bromodomain inhibitor response and demonstrate the need to develop strategies to co-target MYC along with BET bromodomain inhibition in resistant cancer cells. This evidence concerns the gene MYC and cancer.